vs
Dream Finders Homes, Inc.（DFH）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Dream Finders Homes, Inc.的季度营收约是Royalty Pharma plc的1.9倍（$1.2B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 4.8%，领先29.6%），Royalty Pharma plc同比增速更快（4.8% vs -22.3%），过去两年Dream Finders Homes, Inc.的营收复合增速更高（21.0% vs 4.6%）
美国住宅建筑商Dream Finders Homes主要建造并销售独栋住宅、联排别墅等覆盖入门级到高端档次的居住物业，业务布局美国多个高速增长区域，同时为购房者提供按揭融资、产权保险、房屋保修等配套服务，覆盖各类客户群体。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
DFH vs RPRX — 直观对比
营收规模更大
DFH
是对方的1.9倍
$622.0M
营收增速更快
RPRX
高出27.0%
-22.3%
净利率更高
RPRX
高出29.6%
4.8%
两年增速更快
DFH
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $622.0M |
| 净利润 | $58.8M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 6.4% | 62.4% |
| 净利率 | 4.8% | 34.4% |
| 营收同比 | -22.3% | 4.8% |
| 净利润同比 | -54.9% | 2.9% |
| 每股收益（稀释后） | $0.57 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DFHRPRX
| Q4 25 | $1.2B | $622.0M | ||
| Q3 25 | $969.8M | $609.3M | ||
| Q2 25 | $1.2B | $578.7M | ||
| Q1 25 | $989.9M | $568.2M | ||
| Q4 24 | $1.6B | $593.6M | ||
| Q3 24 | $1.0B | $564.7M | ||
| Q2 24 | $1.1B | $537.3M | ||
| Q1 24 | $827.8M | $568.0M |
净利润DFHRPRX
| Q4 25 | $58.8M | $214.2M | ||
| Q3 25 | $47.0M | $288.2M | ||
| Q2 25 | $56.6M | $30.2M | ||
| Q1 25 | $54.9M | $238.3M | ||
| Q4 24 | $130.5M | $208.2M | ||
| Q3 24 | $70.7M | $544.0M | ||
| Q2 24 | $80.9M | $102.0M | ||
| Q1 24 | $54.5M | $4.8M |
毛利率DFHRPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 19.2% | — | ||
| Q1 24 | 18.0% | — |
营业利润率DFHRPRX
| Q4 25 | 6.4% | 62.4% | ||
| Q3 25 | 6.3% | 70.1% | ||
| Q2 25 | 6.4% | 36.3% | ||
| Q1 25 | 7.2% | 94.0% | ||
| Q4 24 | 10.8% | 60.9% | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | 10.0% | 50.2% | ||
| Q1 24 | 8.6% | -13.0% |
净利率DFHRPRX
| Q4 25 | 4.8% | 34.4% | ||
| Q3 25 | 4.8% | 47.3% | ||
| Q2 25 | 4.9% | 5.2% | ||
| Q1 25 | 5.5% | 41.9% | ||
| Q4 24 | 8.4% | 35.1% | ||
| Q3 24 | 7.0% | 96.3% | ||
| Q2 24 | 7.7% | 19.0% | ||
| Q1 24 | 6.6% | 0.8% |
每股收益（稀释后）DFHRPRX
| Q4 25 | $0.57 | $0.49 | ||
| Q3 25 | $0.47 | $0.67 | ||
| Q2 25 | $0.56 | $0.07 | ||
| Q1 25 | $0.54 | $0.55 | ||
| Q4 24 | $1.28 | $0.46 | ||
| Q3 24 | $0.70 | $1.21 | ||
| Q2 24 | $0.81 | $0.23 | ||
| Q1 24 | $0.55 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $234.8M | $618.7M |
| 总债务越低越好 | $1.6B | $9.0B |
| 股东权益账面价值 | $1.4B | $9.7B |
| 总资产 | $3.7B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.13× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资DFHRPRX
| Q4 25 | $234.8M | $618.7M | ||
| Q3 25 | $251.0M | $938.9M | ||
| Q2 25 | $210.3M | $631.9M | ||
| Q1 25 | $297.5M | $1.1B | ||
| Q4 24 | $274.4M | $929.0M | ||
| Q3 24 | $204.9M | $950.1M | ||
| Q2 24 | $274.8M | $1.8B | ||
| Q1 24 | $239.4M | $843.0M |
总债务DFHRPRX
| Q4 25 | $1.6B | $9.0B | ||
| Q3 25 | $1.8B | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $1.3B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益DFHRPRX
| Q4 25 | $1.4B | $9.7B | ||
| Q3 25 | $1.4B | $9.6B | ||
| Q2 25 | $1.3B | $9.5B | ||
| Q1 25 | $1.3B | $9.8B | ||
| Q4 24 | $1.2B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $1.0B | $9.8B | ||
| Q1 24 | $968.7M | $9.9B |
总资产DFHRPRX
| Q4 25 | $3.7B | $19.6B | ||
| Q3 25 | $3.8B | $19.3B | ||
| Q2 25 | $3.7B | $18.3B | ||
| Q1 25 | $3.5B | $17.6B | ||
| Q4 24 | $3.3B | $18.2B | ||
| Q3 24 | $3.3B | $18.0B | ||
| Q2 24 | $3.0B | $17.7B | ||
| Q1 24 | $2.7B | $16.1B |
负债/权益比DFHRPRX
| Q4 25 | 1.13× | 0.92× | ||
| Q3 25 | 1.29× | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 1.03× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $143.6M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $136.0M | — |
| 自由现金流率自由现金流/营收 | 11.2% | — |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | 2.44× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $-126.4M | — |
8季度趋势，按日历期对齐
经营现金流DFHRPRX
| Q4 25 | $143.6M | $827.1M | ||
| Q3 25 | $-131.0M | $702.6M | ||
| Q2 25 | $-68.5M | $364.0M | ||
| Q1 25 | $-44.7M | $596.1M | ||
| Q4 24 | $306.5M | $742.5M | ||
| Q3 24 | $-205.0M | $703.6M | ||
| Q2 24 | $-110.6M | $658.2M | ||
| Q1 24 | $-247.5M | $664.6M |
自由现金流DFHRPRX
| Q4 25 | $136.0M | — | ||
| Q3 25 | $-135.7M | — | ||
| Q2 25 | $-78.8M | — | ||
| Q1 25 | $-47.9M | — | ||
| Q4 24 | $302.6M | — | ||
| Q3 24 | $-222.5M | — | ||
| Q2 24 | $-112.4M | — | ||
| Q1 24 | $-249.6M | — |
自由现金流率DFHRPRX
| Q4 25 | 11.2% | — | ||
| Q3 25 | -14.0% | — | ||
| Q2 25 | -6.8% | — | ||
| Q1 25 | -4.8% | — | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | -22.1% | — | ||
| Q2 24 | -10.6% | — | ||
| Q1 24 | -30.2% | — |
资本支出强度DFHRPRX
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.3% | — |
现金转化率DFHRPRX
| Q4 25 | 2.44× | 3.86× | ||
| Q3 25 | -2.79× | 2.44× | ||
| Q2 25 | -1.21× | 12.06× | ||
| Q1 25 | -0.81× | 2.50× | ||
| Q4 24 | 2.35× | 3.57× | ||
| Q3 24 | -2.90× | 1.29× | ||
| Q2 24 | -1.37× | 6.45× | ||
| Q1 24 | -4.54× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DFH
| Midwest Segment | $454.2M | 37% |
| Southeast Segment | $397.5M | 33% |
| Mid Atlantic Segment | $307.3M | 25% |
| Financial Services Segment | $53.7M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
